Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or...
Reexamination Certificate
2006-05-16
2006-05-16
Coe, Susan (Department: 1655)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
C435S025000, C436S084000
Reexamination Certificate
active
07045282
ABSTRACT:
Kidney disease is diagnosed by measuring urinary catalytic iron in humans. Progressive kidney disease is treated by administering an iron chelator to humans. In particular, the progression of kidney disease essentially can be halted and the severity of kidney disease can be reduced by the administration of iron chelators to humans afflicted with a progressive kidney disease. The methods include measuring catalytic iron content in urine in a human afflicted with a progressive kidney disease and administering an iron chelator to the human. The method can include measuring total urinary protein content, blood urea nitrogen or creatinine in a blood sample before, during or after the administration of an iron chelator.
REFERENCES:
patent: 4684482 (1987-08-01), Green
patent: 5047329 (1991-09-01), Suzuki
patent: 5047421 (1991-09-01), Green
patent: 5091180 (1992-02-01), Walker et al.
patent: 5721209 (1998-02-01), Horwitz et al.
patent: 5811127 (1998-09-01), Milstein et al.
patent: 6206849 (2001-03-01), Martin et al.
patent: 6383817 (2002-05-01), Schwartz
patent: 6589966 (2003-07-01), Torti et al.
patent: 6706287 (2004-03-01), Ranganathan et al.
patent: 2003/0064929 (2003-04-01), Duranton et al.
patent: 2005/0026814 (2005-02-01), Shah
patent: 40 08 323 (1991-09-01), None
patent: 05000949 (1993-01-01), None
patent: WO 88/04925 (1988-07-01), None
patent: WO 90/04584 (1990-05-01), None
patent: WO 91 07956 (1991-06-01), None
patent: WO 94/01770 (1994-01-01), None
patent: WO 98/09626 (1998-03-01), None
patent: WO 00 13706 (2000-03-01), None
patent: WO 00/54784 (2000-09-01), None
Suboonnanonda, A., et al., “Renal tubular function in β-thalassemia”,Pediatr Nephrol,12:280-283.
Ong-ajyooth, L., et al., “Renal Function in Adult Beta-Thalassemia/Hb E Disease”,Nephron,78:156-161 (1998).
Guasch, A., et al., “Evidence that Microdelections in the α Globin Gene Protect Against the Development of Sickle Cell Glomerulopathy in Humans”,J Am Soc Nephrol,10:1014-1019 (1999).
Loebstein, R., et al., “Diabetic Nephropathy in Hypertransfused Patients with β-Thalassemia”,Diabetes Care,21(8):1306-1309 (1998).
Ongajyooth, L., et al., “Glomerulonephritis in β-thalassemia Hb-E Disease: Clinical Manifestations, Histopathologic Studies and Outcome”,J Med Assoc Thai,78(3):119-126 (1995).
Aoki, R.Y., et al., “Microalbuminuria in Sickle Cell Disease”,Brazilian J Med Biol Res,23:1103-1106 (1990).
Katopodis, K.P., et al., “Renal Abnormalities in Patients with Sickle Cell-Beta Thalassemia”,Journal of Nephrology,10(3):163-167 (1997).
Pham, P.-T.T., et al., “Renal abnormalities in sickle cell disease”,Kidney International,57:1-8 (2000).
Kontoghiorghes, G.J., et al., “Simple Synthesis of the Potent Iron Chelators 1-Alkyl-3-hydroxy-2-methylpyrid-4-ones”,Inorganica Chimica Acta.,136:L11-L12 (1987).
Falk, R.J., et al., “Prevalence and Pathologic Features of Sickle Cell Nephropathy and Response to Inhibition of Angiotensin-Converting Enzyme”,The New England Journal of Medicine,326(14):910-915 (1992).
Guasch, A., et al., “Sickle cell anemia causes a distinct pattern of glomerular dysfunction”,Kidney International,51:826-833 (1997).
Cianciulli, P., et al., “Early detection of nephrotoxic effects in thalassemic patients receiving desferrioxamine therapy”,Kidney International,46:467-470 (1994).
Ueda, N., et al., “Role of ‘catalytic’ iron in an animal model of minimal change nephrotic syndrome”,Kidney International,49:370-373 (1996).
Savill, J., et al., “Mechanisms of glomerular injury”. In “Oxford Textbook of Clinical Nephrology,” 2nded., pp. 404-439, eds., Davidson, A.M., et al., Oxford Univ. Press (1998).
Ueda, N., et al., “In VivoEvidence for a Role of Reactive Oxygen Metabolites in Glomerular Disease”,Kidney: A Current Survey of World Literature,6:143-146 (1997).
Boyce, N.W., et al., “Hydroxyl radical mediation of immune renal injury by desferrioxamine”,Kidney International,30:813-817 (1986).
Baliga, R., et al., “Kidney Iron Status in Passive Heymann Nephritis and the Effect of an Iron-Deficient Diet”,J Am Soc Nephrol,7(8):1183-1188 (1996).
Shah, S.V., “Evidence suggesting a role for hydroxyl radical in passive Heymann nephritis in rats”,The American Physiological Society,F337-F344(1988).
Thakur, V., et al., “Evidence suggesting a role for hydroxyl radical in puromycin aminonucleoside-induced proteinuria”,Kidney International,34:494-499 (1988).
Nankivell, B.J. et al., “The Role of Tubular Iron Accumulation in the Remnant Kidney”,J Am Soc Neprhol,4(8):1598-1607 (1994).
Alfrey, A.C., et al., “Role of iron in the tubulo-interstitial injury in nephrotoxic serum nephritis”,Kidney International,36:753-759 (1989).
El Nahas, A.M., “Mechanisms of experimental and clinical renal scarring” In: “Oxford Textbook of Clinical Nephrology”, 2nded., pp. 1749-1788, eds., Davidson, A.M., et al., Oxford Univ. Press (1998).
Howard R.L., et al., “Urinary albumin, transferring and iron excretion in diabetic patients”,International Society of Nephrology,40:923-926 (1991).
Olivieri, N.F., et al., “Iron-Chelation Therapy with Oral Deferiprone in Patients with Thalassemia Major”,The New England Journal of Medicine,918-922 (1995).
Alfrey A.C., “Toxicity of tubule fluid iron in the nephrotic syndrome”,American Journal of Physiology,263(4):F637-F641 (1992).
Wu, Z-L., et al., “Iron Loading Enhances Susceptibility to Renal Ischemia in Rats,”Renal Failure16(4) : 471-480 (1994).
Baliga, R., et al., “In Vitro and In Vivo Evidence Suggesting a Role for Iron in Cistaplin-induced Nephrotoxicity,”Kidney International53(2) : 394-401 (Feb. 1998).
Harris, D., et al., “Mitrochondrial Function in Rat Renal Cortex in Response to Proteinuria and Iron,” Clinical and Experimental Pharmacology and Physiology 24: 916-922 (Dec. 1997).
Walker, P.D., et al., “Evidence Suggesting a Role for Hydroxyl Radical in Gentamicin-Induced Acute Renal Failure in Rats,”J Clin Invest81:334-341 (1988).
Shah, S.V., et al., “Evidence Suggesting a Role for Hydroxyl Radical in Glycerol-Induced Acute Renal Failure,”Am J Physiol 255,(Renal Fluid Electrolyte Physiol. 24):F438-F443 (1988).
Baliga, R., et al., “Increase in Bleomycin-Detectable Iron in Ischaemia/Reperfusion Injury to Rat Kidneys,”Biochem J 291(3):901-905 (1993).
Kontoghiorghese, G.J., et al., “Studies of Aluminum Mobilization in Renal Dialysis Patients Using the Oral Chelator 1,2-Dimethyl-3-hydroxypyrid-4-one,”Arzneim-Forsch/Drug Res. 44(1):522-526 (1994).
Baliga, R., et al., “Oxidant Mechanisms in Toxic Acute Renal Failure,”Drug Metabolism Reviews 31(4):971-991 (1999).
Walker, P.D., et al., “Gentamicin Enhanced Production of Hydrogen Peroxide by Renal Cortical Mitochondria,”Am J Physiol 253:C495-C499 (1987).
Walker, P.D., et al., “Hydrogen Peroxide Cytotoxicity in LLC-PK, Cells: A Role for Iron,”Kidney Int 40:891-898 (1991).
Abul-Ezz, S.R., et al., “Role of Glutathione in an Animal Model of Myoglobinuric Acute Renal Failure,”Proc Natl Acad Sci 88:9833-9837 (1991).
Ueda, N., et al., “Gentamicin-Induced Mobilization of Iron from Renal Cortical Mitochondria,”Am J Physiol 265(3 Pt. 2):F435-F439 (1993).
Baliga, R., et al., “Evidence for Cytochrome P-450 as a Source of Catalytic Iron in Myoglobinuric Acute Renal Failure,”Kidney Int 49:362-369 (1996).
Baliga, R., et al., “Role of Cytochrome P-450 as a Source of Catalytic Iron in Cisplatin-Induced Nephrotoxicity,”Kidney Int 54:1562-1569 (1998).
Hanss, B.G., et al., “The Iron Chelator Deferoxamine Prevents Contrast Media Induced Acute Renal Failure in the Rabbit.” Presented at the Am
Coe Susan
Hamilton Brook Smith & Reynolds P.C.
Shiva Biomedical LLC
Winston Randall
LandOfFree
Diagnosis and treatment of human kidney diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diagnosis and treatment of human kidney diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnosis and treatment of human kidney diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3633219